Senti Biosciences
SNTI · United States
Share price · SNTI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SNTI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-28.7%
Nothing announced by SNTI that day or the session before.
- 2 Nov 2026+13.9%
Nothing announced by SNTI that day or the session before.
- 30 Oct 2026-23.9%
Nothing announced by SNTI that day or the session before.
- 28 Oct 2026+15.2%
- 22 Oct 2026-12.4%
Nothing announced by SNTI that day or the session before.
- 13 Oct 2026-20.0%
- 14 Aug 2026+16.9%
Nothing announced by SNTI that day or the session before.
- 16 Jul 2026-21.1%
- 15 Jul 2026-39.8%
- 24 Jun 2026+16.8%
Nothing announced by SNTI that day or the session before.
Share of unusual movement by asset
For each asset, the share of SNTI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CD33 and/or FLT3 (activating antigens), EMCN (inhibitory NOT-gate)Cell therapy | Acute Myeloid Leukemia | |
| Phase 1 | GPC3 (CAR-NK, calibrated IL-15)Cell therapy | Hepatocellular Carcinoma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | <$0.1M | $7.8M | $7.9M | $13M-$14M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | <$0.1M | $5.3M | $12M | $4.2M-$7.5M operating cash flow | report ↗ |
| 2025-Q3 | — | $11M | $16M | $18M-$9.4M operating cash flow | report ↗ |
| 2025-Q2 | — | $10M | $25M | $15M-$13M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $9.3M | $37M | $14M-$14M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $8.7M | $14M | $29M-$7.9M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $9.2M | $19M | $11M-$8.3M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $8.8M | $28M | $12M-$12M operating cash flow | report ↗ |
| 2023-Q4 | — | — | $39M+ $0 short-term inv. | $71M-$7.0M operating cash flow | report ↗ |
| 2023-Q3 | $0.3M | $9.1M | $46M+ $0 short-term inv. | $15M-$15M operating cash flow | report ↗ |
| 2023-Q2 | $0.7M | $11M | $40M+ $23M short-term inv. | $19M-$14M operating cash flow | report ↗ |
| 2023-Q1 | $1.0M | $11M | $35M+ $45M short-term inv. | $19M-$16M operating cash flow | report ↗ |
| 2022-Q4 | — | — | $61M+ $41M short-term inv. | $58M-$9.0M operating cash flow | report ↗ |
| 2022-Q3 | $1.5M | $8.1M | $118M | $17M-$10M operating cash flow | report ↗ |
| 2022-Q2 | $1.1M | $9.3M | $143M | $12M-$15M operating cash flow | report ↗ |
| 2022-Q1 | $0.8M | $7.6M | $0.4M | $1.3M-$0.5M operating cash flow | report ↗ |
| 2021-Q3 | $0.9M | $5.4M | $75M | $0.3M-$0.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | <$0.1M | $38M | $20M | $15M-$43M operating cash flow | report ↗ |
Senti Biosciences reported FY2025 revenue of $0.02M versus $0M YoY, and R&D spend of $37.59M, up 9.4% YoY. Cash and equivalents were $19.95M, with a net loss of $61.44M and a quarterly net burn of $61.44M.
The company disclosed updated positive preliminary clinical data from the ongoing Phase 1 trial of SENTI-202 in relapsed/refractory acute myeloid leukemia, along with FDA Regenerative Medicine Advanced Therapy designation for SENTI-202. It also noted continued progress across its Gene Circuit engineered cell therapy pipeline and a focus on disciplined capital management to support key development milestones.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $34M | $52M | $13M-$41M operating cash flow | report ↗ |
| 2023-FY | $2.0M | $32M | $39M+ $0 short-term inv. | $18M-$52M operating cash flow | report ↗ |
| 2022-FY | $3.3M | $34M | $61M+ $41M short-term inv. | $15M-$35M operating cash flow | report ↗ |
| 2021-FY | $2.3M | $22M | $0.9M+ $0 short-term inv. | $14M-$35M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-21 | Lu Timothy K · director, CEO | Tax withholding | 157,312 | — | — | Form 4 |
| 2026-10-21 | Rajangam Kanya · Pres. & Chief Med. & Dev. Off. | Tax withholding | 19,953 | — | — | Form 4 |
| 2026-03-09 | Lu Timothy K · director, CEO | Tax withholding | 80,666 | — | — | Form 4 |
| 2026-03-09 | Rajangam Kanya · Pres. & Chief Med. & Dev. Off. | Tax withholding | 10,757 | — | — | Form 4 |
| 2026-02-02 | Lu Timothy K · director, CEO | Tax withholding | 4,191 | — | — | Form 4 |
| 2026-02-02 | Rajangam Kanya · Pres. & Chief Med. & Dev. Off. | Tax withholding | 1,384 | — | — | Form 4 |
| 2025-07-18 | Baum Bryan Daniel · director | Award / grant (derivative) | 43,900 | — | — | Form 4 |
| 2025-06-25 | Mathers Edward T · director | Award / grant (derivative) | 21,950 | — | — | Form 4 |